keyword
MENU ▼
Read by QxMD icon Read
search

Clinical trials in ibd

keyword
https://www.readbyqxmd.com/read/29777041/evolving-role-of-diet-in-the-pathogenesis-and-treatment-of-inflammatory-bowel-diseases
#1
REVIEW
Arie Levine, Rotem Sigall Boneh, Eytan Wine
Recent advances in basic and clinical science over the last 3 years have dramatically altered our appreciation of the role of diet in inflammatory bowel diseases (IBD). The marked increase in incidence of these diseases along with the important role of non-genetic susceptibility among patients with IBD has highlighted that these diseases have a strong environmental component. Progress in the field of microbiome and IBD has demonstrated that microbiome appears to play an important role in pathogenesis, and that diet may in turn impact the composition and functionality of the microbiome...
May 18, 2018: Gut
https://www.readbyqxmd.com/read/29771924/obesity-and-response-to-anti-tumor-necrosis-factor-%C3%AE-agents-in-patients-with-select-immune-mediated-inflammatory-diseases-a-systematic-review-and-meta-analysis
#2
Siddharth Singh, Antonio Facciorusso, Abha G Singh, Niels Vande Casteele, Amir Zarrinpar, Larry J Prokop, Eduardo L Grunvald, Jeffrey R Curtis, William J Sandborn
OBJECTIVES: We sought to evaluate the association between obesity and response to anti-tumor necrosis factor-α (TNF) agents, through a systematic review and meta-analysis. METHODS: Through a systematic search through January 24, 2017, we identified randomized controlled trials (RCTs) or observational studies in adults with select immune-mediated inflammatory diseases-inflammatory bowel diseases (IBD), rheumatoid arthritis (RA), spondyloarthropathies (SpA), psoriasis and psoriatic arthritis (PsA)-treated with anti-TNF agents, and reporting outcomes, stratified by body mass index (BMI) categories or weight...
2018: PloS One
https://www.readbyqxmd.com/read/29771163/review-of-saccharomyces-boulardii-as-a-treatment-option-in-ibd
#3
Kavitha Sivananthan, Andreas Munk Petersen
CONTEXT: Review of the yeast Saccharomyces boulardii as a treatment option for the inflammatory bowel diseases (IBD) ulcerative colitis and Crohn's disease. OBJECTIVE: IBD is caused by an inappropriate immune response to gut microbiota. Treatment options could therefore be prebiotics, probiotics, antibiotics and/or fecal transplant. In this review, we have looked at the evidence for the yeast S. boulardii as a treatment option. MATERIAL AND METHODS: Searches in PubMed and the Cochrane Library with the MeSH words 'Saccharomyces boulardii AND IBD', 'Saccharomyces boulardii AND Inflammatory Bowel Disease', 'Saccharomyces boulardii AND ulcerative colitis' and 'Saccharomyces boulardii AND Crohn's disease' gave total a total of 80 articles...
May 17, 2018: Immunopharmacology and Immunotoxicology
https://www.readbyqxmd.com/read/29766731/-current-and-prospective-biologics-and-small-molecules-in-the-treatment-of-inflammatory-bowel-diseases
#4
Milan Buc
Crohns disease (CD) and ulcerative colitis (UC) belong to chronic inflammatory bowel diseases, which are induced by autoimmune processes. While CD is characterized by over-activity of Th1, ILC1, and MAIT cells, UC is mediated by exaggerated activities of Th2 and ILC2 cells and cytokines they produce. Knowledge of the pathogenesis enabled a rational therapy based mostly on biologics and small molecules. TNF is the principal proinflammatory cytokine in both diseases. Anti-TNF monoclonal antibodies, mostly infliximab or adalimumab were therefore introduced to their treatment...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29761611/multidisciplinary-team-meetings-appear-to-be-effective-in-inflammatory-bowel-disease-management-an-audit-of-process-and-outcomes
#5
Mutaz Ferman, Amanda H Lim, Monowar Hossain, Glenn W Siow, Jane M Andrews
BACKGROUND: Multidisciplinary team meetings (MDTMs) have proven efficacy in cancer management. Whilst widely implemented in inflammatory bowel disease (IBD) care, their value is yet to be investigated. We reviewed the performance of MDTMs for IBD patients. METHODS: Retrospective review of MDTMs from March 2013 to July 2016. Each patient's first MDTM was considered. Data collected included: report production and location, disease factors, recommendation(s), implementation and barriers to implementation...
May 14, 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29761573/using-fat-to-fight-disease-a-systematic-review-of-non-homologous-adipose-derived-stromal-stem-cell-therapies
#6
REVIEW
Marjorie E Bateman, Amy L Strong, Jeffrey M Gimble, Bruce A Bunnell
OBJECTIVE: The objective of this review is to describe the safety and efficacy of ASC and SVF in treating common diseases and the next steps in research that must occur prior to clinical use. EVIDENCE REVIEW: Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta-analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients...
May 15, 2018: Stem Cells
https://www.readbyqxmd.com/read/29760697/hookworm-secreted-extracellular-vesicles-interact-with-host-cells-and-prevent-inducible-colitis-in-mice
#7
Ramon M Eichenberger, Stephanie Ryan, Linda Jones, Geraldine Buitrago, Ramona Polster, Marcela Montes de Oca, Jennifer Zuvelek, Paul R Giacomin, Lindsay A Dent, Christian R Engwerda, Matthew A Field, Javier Sotillo, Alex Loukas
Gastrointestinal (GI) parasites, hookworms in particular, have evolved to cause minimal harm to their hosts, allowing them to establish chronic infections. This is mediated by creating an immunoregulatory environment. Indeed, hookworms are such potent suppressors of inflammation that they have been used in clinical trials to treat inflammatory bowel diseases (IBD) and celiac disease. Since the recent description of helminths (worms) secreting extracellular vesicles (EVs), exosome-like EVs from different helminths have been characterized and their salient roles in parasite-host interactions have been highlighted...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29756637/withdrawal-of-immunosuppressant-or-biologic-therapy-for-patients-with-quiescent-crohn-s-disease
#8
REVIEW
Ray K Boyapati, Joana Torres, Carolina Palmela, Claire E Parker, Orli M Silverberg, Sonam D Upadhyaya, Tran M Nguyen, Jean-Frédéric Colombel
BACKGROUND: Crohn's disease (CD) is a chronic, relapsing and remitting disease of the gastrointestinal tract that can cause significant morbidity and disability. Current treatment guidelines recommend early intervention with immunosuppressant or biological therapy in high-risk patients with a severe disease phenotype at presentation. The feasibility of therapeutic de-escalation once remission is achieved is a commonly encountered question in clinical practice, driven by patient and clinician concerns regarding safety, adverse events, cost and national regulations...
May 12, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29746636/emergence-of-inflammatory-bowel-disease-during-treatment-with-secukinumab
#9
María José Fobelo Lozano, Reyes Serrano Giménez, Manuel Castro Fernández
Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. On the other hand, the drug fact sheet states that secukinumab should be used with caution in patients with inflammatoy bowel disease...
May 9, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29743832/management-of-inflammatory-bowel-disease-in-older-persons-evolving-paradigms
#10
REVIEW
Saurabh Kedia, Jimmy K Limdi, Vineet Ahuja
The incidence and prevalence of inflammatory bowel disease (IBD) is increasing, and considering the aging population, this number is set to increase further in the future. The clinical features and natural history of elderly-onset IBD have many similarities with those of IBD in younger patients, but with significant differences including a broader differential diagnosis. The relative lack of data specific to elderly patients with IBD, often stemming from their typical exclusion from clinical trials, has made clinical decision-making somewhat challenging...
April 2018: Intestinal Research
https://www.readbyqxmd.com/read/29742274/safety-of-tildrakizumab-for-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-three-randomised-controlled-trials
#11
A Blauvelt, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaci, Q Li, N Cichanowitz, S Green, C La Rosa
BACKGROUND: Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated. OBJECTIVES: Safety/tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from 3 randomised controlled trials for moderate-to-severe psoriasis. METHODS: Data pools for the placebo-controlled (up to 16 weeks) and full-trial periods (up to 64 weeks) were analysed (N=2081). RESULTS: In the placebo-controlled period, frequencies of treatment-emergent adverse events (TEAEs; range=47...
May 9, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29740202/anti-integrin-therapy-for-inflammatory-bowel-disease
#12
REVIEW
Sung Chul Park, Yoon Tae Jeen
In inflammatory bowel disease (IBD), tumor necrosis factor plays an important role in mediating inflammation, but several other pathways are also involved in eliciting an inflammatory response. One such pathway is the invasion of the intestinal mucosa by leukocytes. Leukocytes within the systemic circulation move to sites of inflammation, and blocking this pathway could be an important treatment strategy for IBD. Anti-integrin therapy blocks the action of integrin on the surface of circulating immune cells and endothelial cell adhesion molecules, thereby inhibiting the interactions between leukocytes and intestinal blood vessels...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29737503/a-programme-for-risk-assessment-and-minimisation-of-progressive-multifocal-leukoencephalopathy-developed-for-vedolizumab-clinical-trials
#13
Asit Parikh, Kristin Stephens, Eugene Major, Irving Fox, Catherine Milch, Serap Sankoh, Michael H Lev, James M Provenzale, Jesse Shick, Mark Patti, Megan McAuliffe, Joseph R Berger, David B Clifford
INTRODUCTION: Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory biologics. Whether the risk of PML with an investigational agent is proven (e.g. extrapolated from relevant experience, such as a class effect) or merely theoretical, the serious consequences of acquiring PML require careful risk minimisation and assessment...
May 8, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29722812/antibiotics-in-ibd-still-a-role-in-the-biological-era
#14
Oren Ledder, Dan Turner
Despite compelling evidence pointing to a critical role of gut microflora in inflammatory bowel disease (IBD) pathogenesis, the role of antibiotics in clinical practice remains limited, largely due to heterogeneous trials with often conflicting evidence. In this review, we revisit previous randomized controlled trials and high-quality uncontrolled studies in an effort to better elucidate the role of antibiotics in contemporary treatment algorithms. The most established role of antibiotics is in perianal Crohn's disease (CD), utilizing ciprofloxacin with or without metronidazole often as an adjunct to biological therapy...
May 2, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29718218/current-landscape-of-telemedicine-practice-in-inflammatory-bowel-disease
#15
Seema A Patil, Raymond K Cross
Inflammatory bowel disease (IBD), comprised of Crohn's disease and ulcerative colitis, affects 1.6 million people in the United States. Although effective medical treatments exist to treat the disease, outcomes are still suboptimal. The reasons for poor outcomes vary but include nonadherence to therapy, inadequate monitoring of patients, limited access to IBD specialty care, concurrent psychiatric disease, limited patient knowledge of the disease and treatments, and patient provider discordance. Telemedicine is a candidate intervention that can be used to improve patient outcomes through more frequent monitoring, patient self-management, delivery of education (patient and provider), and to increase access to multidisciplinary IBD care...
April 28, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29709540/implications-of-pharmacogenomics-to-the-management-of-ibs
#16
REVIEW
Michael Camilleri
The objectives are to review the role of pharmacogenomics in drug metabolism of medications typically used in patients with irritable bowel syndrome (IBS) focusing predominantly on cytochrome P450 metabolism. Other aims are to provide examples of genetic variation of receptors or intermediary pathways that are targets for IBS drugs and to critically appraise the situations where precision medicine is impacting health in IBS. Pharmacogenomics impacts both pharmacokinetics and pharmacodynamics. Although large clinical trials have not incorporated testing for genetic variations that could impact the efficacy of medications in IBS, there are therapeutic advantages to inclusion of pharmacogenomics testing for individual patients, as has been demonstrated particularly in the treatment with central neuromodulators in psychiatry practice...
April 27, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29696058/our-20-year-experience-with-experimental-colonic-anastomotic-healing
#17
REVIEW
Dimitrios Raptis, Manousos-Georgios Pramateftakis, Ioannis Kanellos
Aim: To present our experience with experimental colonic anastomoses and compare it with the results of other experienced researchers. Materials and Method: The published experimental studies of our research group up to 1996, as well as results of other researchers in this field, are demonstrated and discussed. Different actions of administered substances on the anastomotic healing were compared and represented. Various chemotherapeutic agents were evaluated in experimental models without colorectal cancer as independent risk factors for the anastomotic healing...
January 2018: Journal of Medicine and Life
https://www.readbyqxmd.com/read/29688797/progress-with-infliximab-biosimilars-for-inflammatory-bowel-disease
#18
Zsuzsanna Kurti, Lorant Gonczi, Peter L Lakatos
Biological therapies have revolutionized the treatment of inflammatory bowel diseases (IBD) in the last two decades. Though biological drugs are effective, their use is associated with high costs and access to biological agents varies among countries. As the patent for the reference products expired, the advent of biosimilar monoclonal antibodies has been expected. Biosimilars represent less expensive alternatives compared to the reference product. Areas covered: In this review, authors will review the literature on the clinical efficacy, safety and immunogenicity of current and future biosimilar infliximabs...
April 24, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29685744/update-on-biosimilars-in-inflammatory-bowel-disease-position-and-recommendations-in-mexico
#19
A Mayoral-Zavala, A Esquivel-Aguilar, C M Del Real-Calzada, Y Gutiérrez-Grobe, J Ramos-García, J L Rocha-Ramírez, M F Rojas-Illanes, B Rubio-Martínez, X Sánchez-Chávez, J K Yamamoto-Furusho
The biotechnology-derived medicines known as biosimilars are defined as non-originator treatments that have demonstrated quality, efficacy, and safety comparable to the reference biologic drug. Clinical trials have shown that the infliximab biosimilar, CT-P13, and the candidates for the adalimumab biosimilars, ABP 501 and ZRC 3197, are not significantly different, with respect to efficacy and safety, from the originator drugs in patients with other autoimmune diseases. However, controversy has arisen over the use of biosimilars in inflammatory bowel disease, due to the incipient evidence not only in patients with no previous biotechnology treatment, but also in patients in remission, that could be switched to a biosimilar for non-medical reasons...
April 20, 2018: Revista de Gastroenterología de México
https://www.readbyqxmd.com/read/29680446/nutraceuticals-in-rodent-models-as-potential-treatments-for-human-inflammatory-bowel-disease
#20
REVIEW
Naga K R Ghattamaneni, Sunil K Panchal, Lindsay Brown
Inflammatory Bowel Disease (IBD) is characterized by chronic inflammation of all or part of the digestive tract. Nutraceuticals include bioactive compounds such as polyphenols with anti-inflammatory activities, thus these products have the potential to treat chronic inflammatory diseases. We have emphasized the role of nutraceuticals in ameliorating the symptoms of IBD in rodent models of human IBD through modulation of key pathogenic mechanisms including dysbiosis, oxidative stress, increased inflammatory cytokines, immune system dysregulation, and inflammatory cell signaling pathways...
April 19, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
keyword
keyword
74383
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"